Evidence map›Paper›PMID 39487903›Full record

ArticleCEN case reports2025

Acute tubulointerstitial nephritis associated with infliximab therapy in a patient with Crohn's disease: a case report.

Naif Alghamdi, Fahad Alshehri, Sultan Alhazza, Fahad Bhutto, Azhari Alhassan, Mohammed Kechrid, Dhafer Alshehri, Kadi Alshammari, Talal Assiri, Ohoud Assiri and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Naif AlghamdiInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia. dr.naif90@gmail.com.
Fahad AlshehriInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Sultan AlhazzaInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Fahad BhuttoInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Azhari AlhassanInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Mohammed KechridInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Dhafer AlshehriInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Kadi AlshammariInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Talal AssiriInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Ohoud AssiriInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Emad DarewshInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Mohammed AliInternal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Ruba QadriInternal Medicine Department, Security Forces Hospital Program, Riyadh, Saudi Arabia.
Yasser AlahmadiInternal Medicine Department, Security Forces Hospital Program, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 39-year-old man who presented with a history of generalized fatigue, nausea, subjective fever with rigors, and renal dysfunction after receiving infliximab (IFX) therapy for Crohn's disease. A renal biopsy revealed acute tubulointerstitial nephritis (ATIN). After other causes of acute kidney injury were excluded, steroid therapy was initiated, his fever subsided, and kidney function improved. From this case report, infliximab could be a rare cause of elevated kidney function and that it should be not considered a completely safe treatment or disregarded as potential cause of ATIN.

Indexed as

Crohn DiseaseGastrointestinal AgentsInfliximabNephritis, InterstitialAdultBiopsyHumansKidneyMaleTreatment OutcomeGastrointestinal AgentsInfliximabAcute tubulointerstitial nephritisCrohn’s diseaseInfliximab

Identifiers

PMID39487903
PMCPMC11958843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.